Get Free Trial
News & Analysis
On The Fly
About The Fly
Instant updates and real-time market news.
Five Prime initiated with a Buy at Nomura
Nomura initiated Five Prime with a Buy and a $94 price target.
Leerink major pharma & biotech analyst holds analyst/industry conference call
Biotech Analyst Schmidt and Major Pharmaceuticals Analyst Fernandez, along with University of Chicago Departments of Pathology & Medicine, Professor Dr. Thomas F. Gajewski, discuss the tumor micro-environment on an Analyst/Industry conference call to be held on May 11 at 2 pm.
Five Prime weakness overdone, says Wells Fargo
After a trial of the OPDIVO cancer treatment of Five Prime's (FPRX) partner, Bristol Myers Squibb (BMY), showed disappointing results, Wells Fargo thinks that the nearly 9% decline in Five Prime's stock was overdone. The firm thinks that it's "premature" to determine that Merck's (MRK) Keytruda has overtaken OPDIVO. The firm believes that Five Prime's OPDIVO can redeem itself in upcoming studies, and it thinks that Five Prime's stock can advance if the actor-1 receptor is proven to be a worthwhile target ,whether or not OPDIVO is shown to be effective. The firm keeps an Outperform rating on Five Prime.
Five Prime initiated with a Buy at Citi
Citi analyst Robyn Karnauskas started Five Prime Therapeutics with a Buy rating and $65 price target. The company has "multiple shots" on goal in various cancers, Karnauskas tells investors in a research note. She believes investors will assign higher value to the Cabiralizumab program once combo data with Opdivo is seen in 2017. The analyst sees fair value for Five Prime shares in the $65-$80 range.
TODAY'S FREE FLY STORIES